– Pivotal clinical program for lorundrostat as a treatment of patients with uncontrolled and resistant hypertension ongoing, with topline data from Advance-HTN and Launch-HTN trials expected in first ...
– Lorundrostat 50 mg dose achieved a 15.4 mmHg absolute reduction and 7.9 mmHg placebo-adjusted reduction (p=0.001), assessed by 24hr ABPM at week 12, with favorable safety and tolerability profile – ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CHICAGO — The addition of lorundrostat, an investigational drug, to the treatment regimen of people with well-treated but uncontrolled and resistant hypertension could be beneficial, new data show.
Lorundrostat showed significant systolic blood pressure reduction in both Launch-HTN and Advance-HTN trials, with favorable safety and tolerability profiles. The Launch-HTN trial achieved a 19.0 mm Hg ...
Please provide your email address to receive an email when new articles are posted on . Once-daily lorundrostat safely lowered 24-hour systolic BP compared with placebo in a phase 2 trial. A ...
Medtronic's Second Randomized, Controlled Renal Denervation Clinical Trial in the U.S. Will Potentially Expand Access to the Symplicity(TM) Renal Denervation System for Even Larger Uncontrolled ...
Three-year findings from the SYMPLICITY HTN-2 trial once again swing the pendulum of support back to the side of renal denervation, showing sustained decreases in blood pressure (BP) in select ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results